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A B S T R A C T
Purpose
Related donor haploidentical hematopoietic cell transplantation (Haplo-HCT) using post-
transplantation cyclophosphamide (PT-Cy) is increasingly used in patients lacking HLA-matched
sibling donors (MSD). We compared outcomes after Haplo-HCT using PT-Cy with MSD-HCT in
patients with lymphoma, using the Center for International Blood and Marrow Transplant Research
registry.
Materials and Methods
We evaluated 987 adult patients undergoing either Haplo-HCT (n = 180) or MSD-HCT (n = 807)
following reduced-intensity conditioning regimens. The haploidentical group received graft-versus-
host disease (GVHD) prophylaxis with PT-Cy with or without a calcineurin inhibitor and myco-
phenolate. The MSD group received calcineurin inhibitor–based GVHD prophylaxis.
Results
Median follow-up of survivors was 3 years. The 28-day neutrophil recovery was similar in the two
groups (95% v 97%; P = .31). The 28-day platelet recovery was delayed in the haploidentical group
compared with the MSD group (63% v 91%; P = .001). Cumulative incidence of grade II to IV acute
GVHD at day 100 was similar between the two groups (27% v 25%; P = .84). Cumulative incidence
of chronic GVHD at 1 year was significantly lower after Haplo-HCT (12% v 45%; P , .001), and this
benefit was confirmed on multivariate analysis (relative risk, 0.21; 95% CI, 0.14 to 0.31; P , .001).
For Haplo-HCT v MSD-HCT, 3-year rates of nonrelapse mortality (15% v 13%; P = .41), relapse/
progression (37% v 40%; P = .51), progression-free survival (48% v 48%; P = .96), and overall
survival (61% v 62%; P = .82) were similar. Multivariate analysis showed no significant difference
between Haplo-HCT and MSD-HCT in terms of nonrelapse mortality (P = .06), progression/relapse
(P = .10), progression-free survival (P = .83), and overall survival (P = .34).
Conclusion
Haplo-HCT with PT-Cy provides survival outcomes comparable to MSD-HCT, with a significantly
lower risk of chronic GVHD.
J Clin Oncol 34:3141-3149. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Despite remarkable advances in lymphoma thera-
peutics, allogeneic hematopoietic cell transplantation
(allo-HCT) remains the only potentially curative
treatment for patients with high-risk relapsed or
refractory lymphomas, including Hodgkin and
aggressive non-Hodgkin lymphomas (NHL) fail-
ing a prior autograft.1-4 However, the inability to
identify an HLA-matched sibling donor (MSD)
and sometimes the prohibitive delays in matched
unrelated donor (URD) availability have been
major barriers.5,6 Nearly all patients have an
available related HLA-haploidentical donor (ie,
a donor with whom they share a single HLA
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haplotype). Historically, attempts to perform T-cell–replete allo-
grafts from haploidentical donors were associated with unaccept-
able rates of graft-versus-host disease (GVHD), nonrelapse mortality
(NRM), and graft rejection.7-9
However, contemporary GVHD prophylactic approaches,
especially post-transplantation cyclophosphamide (PT-Cy), have
reduced the morbidity of T-cell–replete haploidentical HCT
(Haplo-HCT).10 PT-Cy promotes immune tolerance by depleting
rapidly proliferating alloreactive host and donor T cells, while
sparing nonalloreactive memory T cells, regulatory T cells, and
hematopoietic progenitor cells.11 Although single-institution
studies12,13 have shown encouraging results of Haplo-HCT with
PT-Cy in lymphoma, and although a recent registry analysis has
reported comparable outcomes of Haplo-HCT versus matched
URD allo-HCT in patients with lymphoma,14 it remains unclear
whether the greater degree of HLA disparity associated with
haploidentical allografts results in higher NRM and inferior sur-
vival when compared with MSD-HCT, the established standard for
allo-HCT. To address this question, we compared the outcomes of
Haplo-HCT against MSD-HCT in patients with lymphoma, using
the observational database of the Center for International Blood
and Marrow Transplant Research.
MATERIALS AND METHODS
Patients
Included in this analysis are adult (18 years or older) patients with
Hodgkin lymphoma and NHL undergoing their first reduced-intensity or
nonmyeloablative conditioning (RIC/NMA) allo-HCT between 2008 and
2013. Eligible donors included either an MSD or a haploidentical related
donor (mismatched for at least two or more HLA loci). Recipients of
Haplo-HCT were limited to those receiving GVHD prophylaxis with
PT-Cy (with or without a calcineurin inhibitor [CNI] and mycophenolate
mofetil). GVHD prophylaxis in the MSD-HCT group was limited to CNI-
based approaches. Patients receiving ex vivo or in vivo graft manipulation
(T-cell–depleted or CD34 selected grafts) or those undergoing a planned
tandem autologous–allo-HCT were excluded (Data Supplement).
Definitions
The intensity of conditioning regimens was determined using con-
sensus criteria.15 Complete remission (CR) before HCT was defined as
complete resolution of all known areas of disease on radiographic as-
sessments, whereas partial remission (PR) was defined as$ 50% reduction
in the greatest diameter of all sites of known disease and no new sites of
disease. Resistant disease was defined as , 50% reduction in the diameter
of all disease sites or development of new disease sites. Disease risk index
(DRI) was defined as reported previously.16
Study End Points
The primary end point was overall survival (OS); death from any
cause was considered an event, and surviving patients were censored at
last contact. NRM was defined as death without evidence of lymphoma
relapse/progression; relapse was considered a competing risk. Progression/
relapse was defined as progressive lymphoma after HCT or lymphoma re-
currence after a CR; NRMwas considered a competing risk. For progression-
free survival (PFS), a patient was considered to have treatment failure at the
time of progression/relapse or death from any cause. Patients alive without
evidence of disease relapse or progression were censored at last follow-up.
Acute GVHD17 and chronic GVHD were graded as previously described.18,19
Neutrophil recovery was defined as the first of 3 successive days with absolute
neutrophil count $ 500/mL after post-transplantation nadir. Platelet re-
covery was defined as achieving platelet counts $ 20,000/mL for at least 3
consecutive days, unsupported by transfusion for the preceding 7 days. For
neutrophil and platelet recovery, death without the event was considered
a competing risk.
Statistical Analysis
The Haplo-HCT cohort was compared with an MSD-HCT group.
Probabilities of PFS and OS were calculated as described previously.20
Cumulative incidence of NRM, lymphoma progression/relapse, and he-
matopoietic recovery were calculated to accommodate for competing
risks.21 Associations among patient-, disease-, and transplantation-related
variables and outcomes of interest were evaluated using Cox proportional
hazards regression. Backward elimination was used to identify covariates
that influenced outcomes. Covariates with a P , .05 were considered
significant. The proportional hazards assumption for Cox regression was
tested by adding a time-dependent covariate for each risk factor and each
outcome. Covariates violating the proportional hazards assumption were
added as time-dependent covariates in the Cox regression model. In-
teractions between the main effect and significant covariates were ex-
amined. Center effect was examined using the random effect score test22
for OS, PFS, relapse, and NRM. Results are expressed as relative risks (RR).
The variables considered in multivariate analysis (MVA) are shown in the
Data Supplement. All statistical analyses were performed using SAS version
9.3 (SAS Institute, Cary, NC).
RESULTS
Baseline Characteristics
Baseline patient-, disease- and transplantation-related char-
acteristics of the 987 patients receiving MSD-HCT (n = 807) or
Haplo-HCT (n = 180) are shown in Table 1. There was no sig-
nificant difference between the MSD-HCT and Haplo-HCT co-
horts in terms of sex, number of prior therapy lines, bone marrow
or extranodal involvement at HCT, presence of bulky disease, HCT
comorbidity index, chemotherapy sensitivity at HCT, and interval
between diagnosis and allo-HCT. Compared with the MSD cohort,
the Haplo-HCT group included a higher proportion of patients
with advanced age (age$ 60 years, 24% v 35%; P, .001), African
American ethnicity (4% v 15%; P , .001), and Karnofsky per-
formance score (KPS) $ 90 (68% v 79%; P , .001). Although the
proportion of patients with stage III and IV disease at diagnosis was
higher in the MSD cohort (67% v 47%; P = .001), at the time of
allo-HCT, significantly more Haplo-HCT cohort patients had
intermediate or high DRI (75% v 63%; P , .001). The most
common lymphoma histology in the Haplo-HCT and MSD-HCT
groups was diffuse large B-cell lymphoma and follicular lymphoma
(FL), respectively. All patients undergoing Haplo-HCT received
conditioning with fludarabine, cyclophosphamide, and 200 cGy
total body irradiation (TBI), whereas those in the MSD-HCT
group received conditioning with fludarabine plus either an alkylator
and/or 200-cGy TBI. The graft source was an unmanipulated bone
marrow (BM) in 93% of Haplo-HCT and peripheral blood (PB) in
98% of MSD-HCT.
Hematopoietic Recovery
The cumulative incidence of neutrophil recovery at day 28 in
Haplo-HCT and MSD-HCT groups was 95% versus 97%, re-
spectively (P = .31; Table 2). The cumulative incidence of platelet
3142 © 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Ghosh et al
Table 1. Baseline Characteristics of Patients With Lymphoma Reported to







No. of patients 180 807
No. of centersa 21 112
No. of CRF-level data
patients
51 104
Age at HCT, median
(range), years
55 (18-75) 54 (18-77) , .001
18-30 22 (12) 72 (9)
31-40 20 (11) 98 (12)
41-50 24 (13) 136 (17)
51-60 51 (28) 309 (38)
61-70 51 (28) 184 (23)
. 70 12 (7) 8 (, 1)
Male sex 115 (64) 496 (61) .54
Race , .001
White 146 (81) 689 (85)
Black 27 (15) 36 (4)
Otherb 6 (3) 29 (4)
Missing 1 (, 1) 53 (7)
Karnofsky performance
score $ 90
142 (79) 548 (68) , .001
HCT comorbidity index .008
0 77 (43) 327 (41)
1-2 50 (27) 195 (24)
$ 3 53 (29) 236 (29)
Missing 0 49 (6)
Histology .002
Follicular lymphomac 28 (16) 204 (25)
Diffuse large B-cell
lymphomad
65 (36) 189 (23)
Mantle cell lymphoma 21 (12) 113 (14)
Mature T- and NK-cell
lymphomas
22 (12) 123 (15)
Hodgkin lymphoma 44 (24) 178 (22)
Advanced stage (III/IV) at
diagnosis
23 (47) 70 (67) .001
Interval from diagnosis to
HCT, months
.12




16 (31) 26 (25) .007
Unknown 14 (27) 11 (11)
Bulky disease (. 5 cm) at
HCT
5 (10) 8 (8) .86
Bone marrow involved at
HCT
6 (12) 6 (6) .31
Active extranodal
involvement at HCT
18 (35) 26 (25) .28
Lines of prior therapies,
median (range)
3 (1-7) 3 (1-9) .10
Radiation therapy before
HCT
12 (24) 23 (22) .03
Missing 8 (16) 4 (4)
Remission status at HCT .08
Complete remission 70 (39) 327 (41)
Partial remission 97 (54) 366 (45)
Chemotherapy-
refractory
10 (6) 98 (12)
Untreated 2 (1) 9 (1)
Unknown 1 (, 1) 7 (, 1)
Disease risk index at HCT , .001
Low 45 (25) 302 (37)
Intermediate 122 (68) 417 (52)
High 12 (7) 88 (11)
Missing 1 (, 1) 0
(continued in next column)
Table 1. Baseline Characteristics of Patients With Lymphoma Reported to
the Center for International Blood and Marrow Transplant Research From








69 (38) 397 (49) .008
Conditioning regimen , .001
Flu/Bu 0 221 (27)
Flu/Cy with or without
rituximab
0 204 (25)
Flu/Cy/200 cGy TBI 180 34 (4)
Flu/Mel with or without
rituximab
0 237 (29)
Flu/200 cGy TBI with or
without rituximab
0 111 (14)
TBI in conditioning 180 145 (18) , .001
Graft type , .001
Bone marrow 168 (93) 15 (2)
Peripheral blood 12 (7) 792 (98)
Female donor to male
recipient




2/+ 39 (22) 162 (20)
Other 140 (77) 629 (78)
Missing 1 (, 1) 16 (2)
GVHD prophylaxis , .001
Post-transplant Cyf 180 (100) 0
CNI + MMF with or
without othersg
0 247 (31)










37 (6-73) 36 (3-76)
NOTE. Italicized text indicates variables available in CRF-level data patients.
Abbreviations: Bu, busulfan; CMV, cytomegalovirus; CNI, calcineurin inhibitor;
CRF, comprehensive report form; Cy, cyclophosphamide; Flu, fludarabine;
GVHD, graft-versus-host disease; HCT, hematopoietic cell transplantation;
Mel, melphalan; MMF, mycophenolate mofetil; MSD, HLA-matched sibling
donor; MTX, methotrexate; NK, natural killer; PTCL-NOS, peripheral T-cell
lymphoma not otherwise specified; TBI, total body irradiation; URD, un-
related donor.
aTwenty centers reported performing both haploidentical and HLA-identical
sibling HCT. Ninety-two centers only reported HLA-identical sibling HCTs. Only
one center reported only haploidentical HCT. This center contributed only one
haploidentical HCT case.
bHaploidentical: Asian (n = 5), Native American (n = 1). HLA-identical siblings:
Asian (n = 24), Pacific Islander (n = 2), Native American (n = 3).
cIn the haploidentical versus HLA-identical sibling groups, the proportion of
patients with grade 1 and 2 follicular lymphoma was 15 (54%) versus 143 (70%);
grade 3 follicular lymphoma was eight (28%) versus 37 (18%), and unknown
grade 5 (18%) versus 24 (12%), respectively (overall P = .33).
dTransformed from indolent lymphoma: haploidentical group: n = 5, HLA-
identical siblings: n = 8.
eDetails of mature T-cell and NK-cell neoplasms included in the analysis. For
haploidentical group: PTCL-NOS = 7, angioimmunoblastic T-cell lymphoma = 3,
extranodal NK/T-cell lymphoma= 4, anaplastic large cell lymphoma= 3, others = 5.
For MSD group: PTCL-NOS = 42, angioimmunoblastic T-cell lymphoma = 24,
extranodal NK/T-cell lymphoma = 11, anaplastic large cell lymphoma = 20,
others = 26.
fCNI/MMF/Cy (n = 172), Cy alone (n = 3), Cy/CNI (n = 4), MMF/Cy (n = 1).
gCNI/MMF (n = 240), CNI/MMF/MTX (n = 7).
hCNI/MTX/steroids (n = 8), CNI/MTX (n = 380), CNI/MTX/sirolimus (n = 56).
iCNI/sirolimus (n = 95), CNI alone (n = 21).
www.jco.org © 2016 by American Society of Clinical Oncology 3143
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recovery in Haplo-HCT and MSD-HCT groups at day 28 and
day 100 was 63% versus 91% (P , .001) and 94% versus 96%
(P = .33), respectively.
The median day 100 donor-cell chimerism in haplo-HCT
versus MSD cohorts on unsorted assays was 100% (range, 77 to
100) versus 99% (range, 28 to 100; P = .002). The respective values
for myeloid-cell–specific assays were 100% (range, 0 to 100) versus
99% (range, 13 to 100; P = .41), whereas those for T-cell–specific
assay were 100% (range, 0 to 100) versus 94% (range, 15 to 100;
P , .001). The proportion of patients achieving complete donor-
cell chimerism (ie, $ 95% donor cells) by day 100 in haplo-
HCT versus MSD cohorts on unsorted, myeloid-cell–specific and
T-cell–specific assays was 94% versus 66% (P = .003), 80% versus
58% (P = .35), and 95% versus 48% (P = .001), respectively.
GVHD
The cumulative incidence of grade II to IVacute GVHD at day
100 (Table 2) in the Haplo-HCT cohort was 27% (95% CI, 15 to
40), compared with 25% (95% CI, 17 to 34) in the MSD group
(P = .84). The rates of grades III and IV acute GVHD at day 100
were 8% in both groups (Table 2; Fig 1A). On MVA, there was no
significant difference in the risk of grade II to IV and grade III and
IV acute GVHD between the two groups (Table 3).
The cumulative incidence of chronic GVHD at 1 year
(Table 2; Fig 1B) after Haplo-HCT was 12% (95% CI, 8 to 18)
compared with 45% (95% CI, 41 to 48) in the MSD cohort
(P , .001). MVA showed a significantly reduced risk of any
chronic GVHD (RR, 0.21; 95% CI, 0.14 to 0.31; P,.001), as well
as moderate/severe chronic GVHD (RR, 0.06; P = .005) after
Haplo-HCT relative to MSD-HCT (Table 3).
NRM and Relapse
Among recipients of Haplo-HCT, 1-year NRM was 10% (95%
CI, 6 to 15) compared with 9% (95% CI, 7 to 11) in MSD allografts
(P= .57; Table 2; Fig 1C). OnMVA, compared withMSD-HCT, there
was no significant difference in the risk of NRM with Haplo-HCT
(RR, 1.52; 95%CI, 0.99 to 2.34; P = .06; Table 3). Independent of the
transplant type, KPS, 90 (RR, 2.07; 95% CI, 1.4 to 3.05; P = .002)
and HCT comorbidity index $ 3 (RR, 1.88; 95% CI, 1.22 to 2.90;
P= .004) were associated with higher risk of NRM (Data Supplement).
The cumulative incidence of disease progression/relapse at
3 years was 37% (95% CI, 30 to 44) and 40% (95% CI, 36 to 43) in
the haploidentical and MSD groups, respectively (P = .51; Table 2;
Fig 1D). On MVA, relative to the MSD-HCT group, there was no
significant difference in the risk of progression/relapse after Haplo-
HCT (RR, 0.80; 95% CI, 0.61 to 1.04; P = .10; Table 3). Other
factors associated with higher risk of disease progression/relapse
were lymphoma histology other than FL, not being in CR at allo-
HCT, presence of bulky or extranodal disease at HCT, HCT
performed before 2010, and intermediate or high DRI (Data
Supplement).
PFS and OS
With a median follow-up of 3 years for surviving patients, the
3-year PFS was not significantly different between the Haplo-HCT
(48%; 95% CI, 40 to 56) and MSD-HCT (48%; 95% CI, 44 to 51)
groups (P = .96; Table 2; Fig 1E), and this was confirmed by MVA
(RR of treatment failure, 0.98; 95% CI, 0.77 to 1.23; P = .83;
Table 3). Independent of the transplant type, other predictors of
higher risk of therapy failure included lymphoma histology other
than FL, KPS , 90, not being in CR at allo-HCT, presence of
extranodal or bulky disease, HCT performed before 2010, and
intermediate or high DRI (Data Supplement).
The 3-year OSwas not significantly different in the Haplo-HCT
andMSD-HCT groups at 61% (95%CI, 54 to 69) and 62% (95%CI,
59 to 66), respectively (P = .82; Table 2; Fig 1F), and this was
confirmed by MVA (RR of mortality, 1.14; 95% CI, 0.87 to 1.49;
P = .34; Table 3). Independent of the transplant type, other predictors
of higher risk of mortality included lymphoma histology other than
FL or T-cell NHL, KPS, 90, not being in CR at allo-HCT, presence of
bulky disease, HCT performed before 2010, and intermediate or high
DRI (Data Supplement). PFS and OS stratified according to lym-
phoma histologies are provided in the Data Supplement.
Causes of Death
The most common cause of death in both cohorts was
recurrent/progressive lymphoma: 47% (n = 34) and 52% (n = 151)
in the Haplo-HCT and MSD-HCT groups, respectively (Data
Supplement). Although GVHD was the cause of death in 5%
(n = 13) ofMSD-HCTrecipients, only one death in the haploidentical
group was attributed to this.
Center Effect
Haplo-HCTwas performed at 21 transplant centers compared
with 112 centers performing MSD-HCT. To ensure that outcomes
reported in the current analysis were not driven by institutional
expertise, transplant center effect was examined. We found no
center effect on the hazard of OS (P = .06) and PFS (P = .15), and
the cause-specific hazard of relapse (P = .77) and NRM (P = .24),
using the random effect score test (Data Supplement).
Subset Analysis
Because the predominant graft source differed between the
haploidentical and MSD cohorts, subset MVA of transplantation
outcomes was performed in Haplo-HCT receiving BM grafts
(n = 163) and MSD-HCT receiving PB grafts (n = 774). The
results were in line with the outcomes of entire study population
(Data Supplement).
DISCUSSION
The success of allo-HCT has historically depended on grafts from
donors matched with the recipient at the HLA loci with high-
resolution techniques. Approximately 30% of patients have an
HLA-matched sibling donor, and, in spite of millions of donors
enrolled in transplant registries, HLA-matched URD availability is
driven by ethnicity6 and varies widely across countries. The URD
search process is also prone to logistical challenges, delays,23,24 and
occasionally disease progression before transplantation, especially
in aggressive malignancies.25 The use of haploidentical related
donors can overcome these limitations, but in lymphoma no
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studies have compared this approach with the established gold
standard donor source (ie, MSD-HCT). Here, we performed
a registry analysis comparing outcomes of patients with lym-
phoma undergoing Haplo-HCT using PT-Cy–based GVHD
prophylaxis with patients undergoing MSD-HCT. Our analysis
suggests that survival, risk of relapse/progression, and NRM
were virtually identical for Haplo-HCTand MSD-HCT cohorts.
Second, Haplo-HCTwith PT-Cy was associated with significantly
lower rates of chronic GVHD, and mortality secondary to GVHD
was rare. Finally, nonengraftment was not a concern with similar
neutrophil recovery kinetics in the Haplo-HCT and MSD-HCT
cohorts.
The Haplo-HCT cohort in this study received uniform
conditioning (fludarabine/cyclophosphamide/200-cGy TBI) and
PT-Cy–based GVHD prophylaxis. To ensure a valid comparison,
the eligibility in the MSD-HCT group was limited to condi-
tioning with fludarabine plus an alkylator and/or 200 cGy TBI
and GVHD prophylaxis to CNI-based approaches. Additional
MVA restricted to the MSD-HCT cohort did not show any
differences between individual conditioning and GVHD pro-
phylactic regimens in terms of NRM, progression/relapse, ther-
apy failure, and mortality risk (data not shown). This step ensured
that survival outcomes among MSD-HCT recipients were not
influenced by the heterogeneity of conditioning and GVHD
prophylaxis approaches. Although more patients in the MSD
group had chemorefractory disease and KPS , 90, signifi-
cantly more patients undergoing Haplo-HCT had interme-
diate or high DRI, indicating that the Haplo-HCT cohort
Table 2. Hematopoietic Recovery, GVHD, and Unadjusted Survival Outcomes
Outcome
Haploidentical HLA-Identical Siblings
PNo. Evaluated Probability (95% CI; %) No. Evaluated Probability (95% CI; %)
Neutrophil recovery . 500/uL 179 803
28-day 95 (90 to 98) 97 (95 to 98) .31
100-day 99 (98 to 100) 98 (97 to 99) .07
Platelet recovery $ 20/uL 180 778
28-day 63 (56 to 70) 91 (89 to 93) , .001
100-day 94 (90 to 97) 96 (94 to 97) .33
Acute GVHD (II-IV)* 49 104
100-day 27 (15 to 40) 25 (17 to 34) .84
Acute GVHD (III-IV)* 49 104
100-day 8 (2 to 17) 8 (3 to 14) .92
Acute GVHD (II-IV) 175 789
180-day 51 (43 to 60) 44 (40 to 49) .15
Acute GVHD (III and IV) 175 789
180-day 10 (5 to 17) 18 (15 to 21) .03
Chronic GVHD 178 767
6-month 5 (2 to 9) 24 (21 to 27) , .001
1-year 12 (8 to 18) 45 (41 to 48) , .001
2-year 15 (10 to 21) 52 (49 to 56) , .001
Mild chronic GVHD 47 99
6-month 6 (1 to 15) 5 (2 to 11) .77
1-year 13 (5 to 24) 17 (10 to 25) .56
2-year 13 (5 to 24) 20 (13 to 29) .27
Moderate/severe chronic GVHD 47 99
6-month 2 (0 to 9) 13 (7 to 20) .01
1-year 2 (0 to 9) 26 (18 to 36) , .001
2-year 2 (0 to 9) 33 (24 to 43) , .001
Nonrelapse mortality 180 804
1-year 10 (6 to 15) 9 (7 to 11) .57
2-year 14 (10 to 20) 11 (9 to 14) .27
3-year 15 (10 to 21) 13 (10 to 15) .41
Relapse/progression 180 804
1-year 31 (25 to 38) 30 (27 to 33) .78
2-year 35 (28 to 42) 37 (34 to 41) .61
3-year 37 (30 to 44) 40 (36 to 43) .51
Progression-free survival 180 804
1-year 59 (51 to 66) 61 (58 to 64) .55
2-year 51 (43 to 58) 52 (48 to 55) .78
3-year 48 (40 to 56) 48 (44 to 51) .96
Overall survival 180 807
1-year 77 (70 to 82) 78 (75 to 81) .64
2-year 65 (57 to 72) 68 (65 to 72) .39
3-year 61 (54 to 69) 62 (59 to 66) .82
NOTE. Probabilities of neutrophil and platelet recovery, platelet recovery, acute GVHD, chronic GVHD, treatment-related mortality, and progression/relapse were
calculated using the cumulative incidence estimate. Progression-free survival and overall survival were calculated using the Kaplan-Meier product limit estimate.
Abbreviations: GVHD, graft-versus-host disease.
*Calculated from comprehensive report form–level data only.
www.jco.org © 2016 by American Society of Clinical Oncology 3145
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possibly had more biologically higher-risk patients. The DRI is
a validated tool that stratifies patients into risk groups using type
and status of disease at the time of transplantation.16,26 The delay
in platelet recovery in the Haplo-HCT cohort is likely due to the
application of PT-Cy and has been observed in other recent
reports.27








































































































































Fig 1. (A) Cumulative incidence of grade III and IV acute graft-versus-host disease (GVHD) in recipients of haploidentical donor versus HLA-identical sibling donor
allogeneic hematopoietic cell transplantation. (B) Cumulative incidence of chronic GVHD in recipients of haploidentical donor versus HLA-identical sibling donor allogeneic
hematopoietic cell transplantation. (C) Cumulative incidence of nonrelapse mortality in recipients of haploidentical donor versus HLA-identical sibling donor allogeneic
hematopoietic cell transplantation. (D) Cumulative incidence of lymphoma relapse/progression in recipients of haploidentical donor versus HLA-identical sibling donor
allogeneic hematopoietic cell transplantation. (E) Progression-free survival in recipients of haploidentical donor versus HLA-identical sibling donor allogeneic hematopoietic
cell transplantation. (F) Overall survival in recipients of haploidentical donor versus HLA-identical sibling donor allogeneic hematopoietic cell transplantation.
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The low incidence of chronic GVHD with Haplo-HCT using
the PT-Cy platform in our analysis (12% at 1 year) is in line with
published data.28 Although it is plausible that the low chronic
GVHD rates observed with Haplo-HCT are in part due to the
frequent use of BM as graft source in this cohort, it is important to
point out that unlike myeloablative allografts, in the setting of
RIC transplantation BM grafts have not been consistently shown
to be associated with reduced chronic GVHD risk.29,30 Effective
depletion of alloreactive donor T cells by PT-Cy along with the
use of BM as the predominant graft source are likely major drivers
of reduced chronic GVHD risk after Haplo-HCT in our study.
However, the relative contribution of the graft source (BM v PB)
and PT-Cy in reducing the risk of chronic GVHD cannot be
dissected by the current analysis. The ongoing Novel Approaches
for Graft-versus-Host Disease Prevention Compared to Con-
temporary Controls trial (BMT CTN 1203; NCT02208037) is
evaluating the role of PT-Cy as GVHD prophylaxis in RIC allo-
HCTrecipients. On its completion, we may better understand the
impact of the PT-Cy for GVHD prophylaxis relative to the
standard CNI-based prophylaxis. Although our analysis did not
examine quality of life and other correlates that translate the
reduced chronic GVHD risk to patient-reported outcomes, such
analyses are imperative given the impact of chronic GVHD on
long-term survivorship and will need to be examined in the
prospective setting. Despite lower chronic GVHD in the hap-
loidentical cohort, the risk of relapse was not higher, suggesting
that any graft-versus-lymphoma effects in the Haplo-HCTsetting
are similar to MSD-HCT and independent of clinical chronic
GVHD. Data on the kinetics of post–allo-HCT immune re-
constitution are not captured in the registry; however, there was
no difference in terms of fatal infections between the two groups
(Data Supplement).
To date, no large prospective or registry data are available to
suggest that alternative donor HCT for hematologic malignancies
in general and lymphoma in particular could provide outcomes
comparable to MSD-HCT. Although survival and NRM rates after
mismatched URD or cord blood allografts have in general been
either inferior or comparable to those after matched URD,31,32 no
large studies suggest that such alternative donor sources could
provide outcomes comparable toMSD-HCT. The 3-year NRM and
OS rates (15% and 61%, respectively) after Haplo-HCT in the
current analysis not only compare favorably against prior Center
for International Blood andMarrow Transplant Research data33 for
patients with lymphoma undergoing mismatched URD (3-year
NRM, 44%; OS, 37%) or cord blood (3-year NRM, 37%; OS, 41%)
allo-HCT, but these data for the first time demonstrate that RIC/
NMA Haplo-HCT using the PT-Cy platform provides early post-
HCT survival outcomes comparable to MSD-HCT, while signifi-
cantly reducing the burden of chronic GVHD. It is important to
note that the 3-year OS of NHL-only patients in our study (58%)
seems higher than estimates reported by Kasamon et al12 (47% at
3 years). Possible reasons for this difference include older HCT
era (2003 to 2013), exclusion of young patients, and inclusion of
chronic lymphocytic leukemia and aggressive lymphomas besides
diffuse large B-cell lymphoma in the prior publication.
Similar to other registry-based analyses, there are some ca-
veats to be considered. Any observational study comparing dif-
ferent interventions is subject to preferences of the treating centers/
physicians owing to the complex criteria for selection that underlie
the choice of intervention. More frequent history of autografts in
Table 3. Results of Multivariate Analysis for Outcomes After Haplo-HCT or MSD-HCT
Outcome No. RR
95% CI
PLower Limit Upper Limit
Grade II-IV acute GVHD*
HLA-identical siblings 789 1
Haploidentical 175 1.40 0.99 1.99 .06
Grade III and IV acute GVHD*
HLA-identical siblings 789 1
Haploidentical 175 0.50 0.25 0.98 .45
Chronic GVHD
HLA-identical siblings 712 1
Haploidentical 177 0.21 0.14 0.31 , .001
Moderate/severe chronic GVHD
HLA-identical siblings 99 1
Haploidentical 47 0.06 0.01 0.42 .005
Nonrelapse mortality
HLA-identical siblings 755 1
Haploidentical 180 1.52 0.99 2.34 .06
Progression/relapse
HLA-identical siblings 804 1
Haploidentical 180 0.80 0.61 1.04 .10
Progression-free survival
HLA-identical siblings 804 1
Haploidentical 180 0.98 0.77 1.23 .83
Overall survival
HLA-identical siblings 807 1
Haploidentical 180 1.14 0.87 1.49 .34
Abbreviations: GVHD, graft-versus-host disease; HCT, hematopoietic cell transplantation; MSD, HLA-matched sibling donor; RR, relative risk; URD, unrelated donor.
*Acute GVHD models used logistic regression.
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the MSD-HCT group could be reflective of institutional practice
differences; however, the similar time interval between diagnosis
and allo-HCTand median lines of prior therapies between the two
groups suggest that no one group was overrepresented by lym-
phomas earlier in the disease course. Patients in this study had
various histologies, and although outcomes reported here were
adjusted for lymphoma subtypes, a potential benefit or lack thereof
of one donor source over another for any specific lymphoma
subtype cannot be confirmed. In addition, with the available data
in the registry we cannot evaluate potential differences between the
two cohorts in terms of health care cost effectiveness and resource
use (eg secondary to infectious complications).
In summary, compared with RIC MSD-HCT, Haplo-HCT
with PT-Cy significantly reduces the risk of chronic GVHD
without compromising relapse and survival. RIC/NMA condi-
tioning followed by Haplo-HCTwith PT-Cy should be considered
an acceptable option for patients with lymphoma without MSDs.
As such, this strategy can broaden the timely applicability of allo-
HCT without compromising efficacy and limit the racial barriers
for receiving this potentially curative treatment option. Additional
analyses in collaboration with European Group for Blood and
Marrow Transplantation are being planned to validate these re-
sults in a larger international patient cohort. The results of our
study warrant confirmation in prospective, randomized, controlled
trials.
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